Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer’s disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer’s models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer’s care.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Dawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFH
Professor of Pharmacy Practice
Midwestern University

PRACTICE RESOURCE
Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current evidence on the use of microdose lithium in Alzheimer's disease.
2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's.

Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-375-H01-P
Initial release date: 12/22/2025
Expiration date: 12/22/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram